As part of CRA’s issues leadership initiative to challenge industry thinking on rare diseases, we assembled a panel of CRA experts to discuss the opportunities and challenges posed by the latest therapeutic breakthroughs in conditions that affect fewer than one in 2,000 people. Neil Turner moderates a discussion with Greg Bell, Kevin Brubacher, Ned Kitfield, Cécile Matthews, and Tim Wilsdon.
Patient burden associated with acute & chronic resistant infections
Inspiring stakeholders to take action on antimicrobial resistance (AMR) starts with communicating the current and future burden of...